Thomas Robert
YOU?
Author Swipe
View article: Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR
Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR Open
Introduction Radioembolisation (RE) is gaining traction as a robust treatment option for patients with hepatocellular cancer (HCC) across all cancer stages. RE allows the delivery of targeted high-dose radiation directly to tumours, with r…
View article: The Brain Imaging and Neurophysiology Database: BINDing multimodal neural data into a large-scale repository
The Brain Imaging and Neurophysiology Database: BINDing multimodal neural data into a large-scale repository Open
1 Abstract The Brain Imaging and Neurophysiology Database (BIND) represents one of the largest multi-institutional, multimodal, clinical neuroimaging repositories, comprising 1.8 million brain scans from 38,945 patients, linked to neurophy…
View article: #170 Exome sequencing in patients with Medullary sponge kidney
#170 Exome sequencing in patients with Medullary sponge kidney Open
Background and Aims Medullary sponge kidney (MSK) is characterized by precalyceal dilatation of the renal tubules and recurrent kidney stones (KS). Although etiopathogenesis is unknown, genetic origin is suspected since familial cases have…
View article: Exome Sequencing in Pacific Islanders With Nephropathies of Unknown Origin
Exome Sequencing in Pacific Islanders With Nephropathies of Unknown Origin Open
View article: Multidimensional outcome after endovascular or microsurgical occlusion of ruptured intracranial aneurysms – Comparative analysis of a prospective Swiss multicenter study
Multidimensional outcome after endovascular or microsurgical occlusion of ruptured intracranial aneurysms – Comparative analysis of a prospective Swiss multicenter study Open
After interdisciplinary selection of the most appropriate treatment, similar favorable outcomes can be achieved in alert aSAH patients.
View article: Authors' Reply: Using VNtyper from Whole Exome Sequencing Data to Detect Pathogenic Variants in the MUC1 Gene
Authors' Reply: Using VNtyper from Whole Exome Sequencing Data to Detect Pathogenic Variants in the MUC1 Gene Open
View article: Systematic Screening of Autosomal Dominant Tubulointerstitial Kidney Disease–MUC1 27dupC Pathogenic Variant through Exome Sequencing
Systematic Screening of Autosomal Dominant Tubulointerstitial Kidney Disease–MUC1 27dupC Pathogenic Variant through Exome Sequencing Open
Key Points MUC1 is associated with autosomal dominant tubulointerstitial kidney disease, a genetic disorder progressing to kidney failure. Variations in this gene are not easily diagnosed by conventional methods due to the MUC1 architectur…
View article: Hair-straightening cosmetics containing glyoxylic acid induce crystalline nephropathy
Hair-straightening cosmetics containing glyoxylic acid induce crystalline nephropathy Open
View article: Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy Open
The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failur…
View article: Toward acid- and heparin-free dialysis: the regional anticoagulation approach
Toward acid- and heparin-free dialysis: the regional anticoagulation approach Open
Background In chronic intermittent hemodialysis, heparin is the standard anticoagulant as is the use of acid-containing dialysate. Regional anticoagulation (RA) with a calcium-free, citrate-containing dialysate has been developed. We compa…
View article: Immunoadsorption and Plasma Exchange are Comparable in Anti-Neutrophil Cytoplasmic Antibodies or Anti-Glomerular Basement Membrane Removal Kinetics
Immunoadsorption and Plasma Exchange are Comparable in Anti-Neutrophil Cytoplasmic Antibodies or Anti-Glomerular Basement Membrane Removal Kinetics Open
View article: #958 Development and Validation of a Score Estimating the Probability of obtaining a genetic diagnosis in adults with CKD of uncertain origin
#958 Development and Validation of a Score Estimating the Probability of obtaining a genetic diagnosis in adults with CKD of uncertain origin Open
Background and Aims We aim to derive and validate a score estimating the probability of identifying a variant explicative of the renal phenotype using Exome Sequencing (ES) in adults with CKD of uncertain origin. Method Participants: prosp…
View article: Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry
Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry Open
View article: Diagnosis of Kidney Diseases of Unknown Etiology Through Biopsy-Genetic Analysis
Diagnosis of Kidney Diseases of Unknown Etiology Through Biopsy-Genetic Analysis Open
ES done in patients with biopsy-proven UKD should be considered as a first-line tool for CKD patients with a family history of kidney disease. Combination of ES and kidney biopsy may have major impacts on kidney disease ontology.
View article: #5958 VALUE OF EXOME SEQUENCING “FIRST” FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
#5958 VALUE OF EXOME SEQUENCING “FIRST” FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Open
Background and Aims Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common Mendelian kidney diseases, that can progress to end-stage kidney failure. Pathological variants in PKD1 or PKD2 genes are found in about 78%…
View article: Beyond the kidney biopsy: genomic approach to undetermined kidney diseases
Beyond the kidney biopsy: genomic approach to undetermined kidney diseases Open
Background According to data from large national registries, almost 20%–25% of patients with end-stage kidney disease have an undetermined kidney disease (UKD). Recent data have shown that monogenic disease-causing variants are under-diagn…
View article: Successful weaning versus permanent cerebrospinal fluid diversion after aneurysmal subarachnoid hemorrhage: post hoc analysis of a Swiss multicenter study
Successful weaning versus permanent cerebrospinal fluid diversion after aneurysmal subarachnoid hemorrhage: post hoc analysis of a Swiss multicenter study Open
OBJECTIVE Acute hydrocephalus is a frequent complication after aneurysmal subarachnoid hemorrhage (aSAH). Among patients needing CSF diversion, some cannot be weaned. Little is known about the comparative neurological, neuropsychological, …
View article: Supplementary Tables S1-S5 from Identification of Soluble Candidate Biomarkers of Therapeutic Response to Sunitinib in Medullary Thyroid Carcinoma in Preclinical Models
Supplementary Tables S1-S5 from Identification of Soluble Candidate Biomarkers of Therapeutic Response to Sunitinib in Medullary Thyroid Carcinoma in Preclinical Models Open
Supplementary Tables S1-S5.
View article: Supplementary Tables S1-S5 from Identification of Soluble Candidate Biomarkers of Therapeutic Response to Sunitinib in Medullary Thyroid Carcinoma in Preclinical Models
Supplementary Tables S1-S5 from Identification of Soluble Candidate Biomarkers of Therapeutic Response to Sunitinib in Medullary Thyroid Carcinoma in Preclinical Models Open
Supplementary Tables S1-S5.
View article: Supplementary Table 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
Supplementary Table 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention Open
Supplementary Table 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
View article: Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
View article: Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention Open
Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
View article: Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
Supplementary Movie 1 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
View article: Data from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Data from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non–small cell lung cancer (NSCLC) A549 cells …
View article: Data from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Data from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. We used microarray technology to identify miRNAs that were upregulated by non–small cell lung cancer (NSCLC) A549 cells …
View article: Supplementary Figure, Table and Movie Legends from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Supplementary Figure, Table and Movie Legends from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
Supplementary Figure, Table and Movie Legends from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
View article: Supplementary Figure 1 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
Supplementary Figure 1 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention Open
Supplementary Figure 1 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
View article: Supplementary Tables 1-4 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Supplementary Tables 1-4 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
Supplementary Tables 1-4 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
View article: Supplementary Figures 1-6 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Supplementary Figures 1-6 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death Open
Supplementary Figures 1-6 from miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
View article: Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention Open
Supplementary Figure 2 from Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention